bupropion hydrochloride

FDA Drug Profile — Bupropion Hydrochloride SR, Bupropion Hydrochloride (XL), Bupropion Hydrochloride XL, bupropion hydrochloride, bupropion hydrochloride SR

Drug Details

Generic Name
bupropion hydrochloride
Brand Names
Bupropion Hydrochloride SR, Bupropion Hydrochloride (XL), Bupropion Hydrochloride XL, bupropion hydrochloride, bupropion hydrochloride SR, BUPROPION HYDROCHLORIDE, bupropion, buPropion Hydrochloride XL, BuPROPion Hydrochloride, WELLBUTRIN SR
Application Number
ANDA079095
Sponsor
Actavis Pharma, Inc.
NDC Codes
50
Dosage Forms
TABLET, FILM COATED, EXTENDED RELEASE, POWDER, TABLET, EXTENDED RELEASE, TABLET, FILM COATED
Routes
ORAL
Active Ingredients
BUPROPION HYDROCHLORIDE

Indications and Usage

1 INDICATIONS AND USAGE Bupropion hydrochloride extended-release tablets (XL) are an aminoketone antidepressant, indicated for: treatment of major depressive disorder (MDD) ( 1.1 ) prevention of seasonal affective disorder (SAD) ( 1.2 ) 1.1 Major Depressive Disorder (MDD) Bupropion hydrochloride extended-release tablets (XL) are indicated for the treatment of major depressive disorder (MDD), as defined by the Diagnostic and Statistical Manual (DSM). The efficacy of the immediate-release formulation of bupropion was established in two 4-week controlled inpatient trials and one 6-week controlled outpatient trial of adult patients with MDD. The efficacy of the sustained-release formulation of bupropion in the maintenance treatment of MDD was established in a long-term (up to 44 weeks), placebo-controlled trial in patients who had responded to bupropion in an 8-week study of acute treatment [see Clinical Studies (14.1) ]. 1.2 Seasonal Affective Disorder (SAD) Bupropion hydrochloride extended-release tablets (XL) are indicated for the prevention of seasonal major depressive episodes in patients with a diagnosis of seasonal affective disorder (SAD). The efficacy of bupropion hydrochloride extended-release tablets (XL) in the prevention of seasonal major depressive episodes was established in 3 placebo-controlled trials in adult outpatients with a history of MDD with an autumn-winter seasonal pattern as defined in the DSM [see Clinical Studies (14.2) ].